SCHEMBL25309124

SCHEMBL25309124

CC(C)n1cnc2c(NCc3ccc(-c4ccccn4)cn3)nc(-c3cccc(O)c3)nc21

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 17/20 0.51
CCNA2 P20248 8/20 0.51
CDK9 P50750 7/20 0.51
CCNA1 P78396 6/20 0.51
CCNT1 O60563 6/20 0.51
CDK5 Q00535 6/20 0.51
CDK5R1 Q15078 6/20 0.51
DYRK1A Q13627 5/20 0.51
CSNK1A1 P48729 5/20 0.51
GSK3A P49840 1/20 0.51
GSK3B P49841 1/20 0.51
CCNE1 P24864 13/20 0.50
CDK1 P06493 12/20 0.50
CCNB1 P14635 12/20 0.50
CDK7 P50613 11/20 0.50
CCNH P51946 11/20 0.50
CDK4 P11802 10/20 0.50
CCND1 P24385 10/20 0.50
CCNK O75909 2/20 0.50
CDK12 Q9NYV4 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30518510 1.00 CDK2 (0.51) CDK2CCNA2CDK9CCNA1CCNT1
SCHEMBL25306155 0.87 CDK2 (0.51) CDK2CCNA2CDK9CCNA1CCNT1
SCHEMBL30518549 0.87 CDK2 (0.51) CDK2CCNA2CDK9CCNA1CCNT1
SCHEMBL30518524 0.86 CDK2 (0.51) CDK2CCNA2CDK9CCNA1CCNT1
SCHEMBL25306508 0.86 CDK2 (0.51) CDK2CCNA2CDK9CCNA1CCNT1
SCHEMBL25309353 0.83 CDK1 (0.52) CDK2CCNA2CDK9CCNA1CCNT1
SCHEMBL30518534 0.83 CDK1 (0.52) CDK2CCNA2CDK9CCNA1CCNT1
SCHEMBL25299779 0.83 CDK1 (0.62) CDK2CCNA2CDK9CCNA1CCNT1
SCHEMBL25309378 0.79 CDK2 (0.56) CDK2CCNA2CDK9CCNA1CCNT1
SCHEMBL30518560 0.79 CDK2 (0.56) CDK2CCNA2CDK9CCNA1CCNT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250101023-A1 HETEROARYL DERIVATIVE AND USES THEREOF IUCF-HYU (INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY) (KR) 2025-03-27 US claimed
WO-2023140640-A1 HETEROARYL DERIVATIVE AND USES THEREOF 한양대학교 산학협력단 2023-07-27 WO claimed
US-20250101023-A1 HETEROARYL DERIVATIVE AND USES THEREOF IUCF-HYU (INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY) (KR) 2025-03-27 US disclosed
WO-2023140640-A1 HETEROARYL DERIVATIVE AND USES THEREOF 한양대학교 산학협력단 2023-07-27 WO disclosed
WO-2023140640-A1 HETEROARYL DERIVATIVE AND USES THEREOF 한양대학교 산학협력단 2023-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250101023-A1 HETEROARYL DERIVATIVE AND USES THEREOF ERBB2, ERBB3, FGFR2 CDK2 79/4885CCNA2 577/4885CDK9 1501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.